Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Senti Biosciences, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Senti Biosciences, Inc. (“Senti” or “the Company”) (NASDAQ: SNTI). Investors who purchased Senti securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Senti has violated federal securities laws.
Investigation Details
On April 28, 2025, Senti announced in a press release that “enrollment has been stopped” in the Investigator Sponsored Trial for drug candidate SN301A, “based on the observation of certain dose limiting toxicities.” Following this news, Senti stock dropped 27.2% on the same day.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Senti securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
SNTI — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”